Clinician's Roundtable

Host: Leslie P. Lundt, MD Guest: Kevin Antshel, PhD Does the diagnosis of ADHD qualify an adult for special accommodations under the ADA? ADHD expert Dr. Kevin Antshel explains how the process works to host Dr. Leslie Lundt.

Host: Leslie P. Lundt, MD Guest: Kevin Antshel, PhD Traditional wisdom says that people with ADHD have lower IQs. Is it possible to have ADHD and a high IQ? Syracuse University psychologist Dr. Kevin Antshel joins host Dr. Leslie Lundt to discuss twice exceptional children.

Host: Larry Kaskel, MD Guest: Ezra Cohen, MD Rapamycin has potential anti-cancer activity but poor oral bioavailability. Grapefruit Juice increases the bioavailability of many drugs. In this segment, Dr. Ezra Cohen shares his research in which he tests whether or not grapefruit juice increases the absorbtion of rapamycin and what impact that may have on the cost and distribution of the Drug. Join host Larry Kaskel to learn more.

Host: Sayantani DasGupta, MD, MPH Guest: Rita Charon, MD, PhD Narrative Medicine: a return to traditional clinical practice or a new way to care for patients? Host Dr. Sayantani DasGupta speaks with clinician and literary scholar Dr. Rita Charon, Founder and Director of the Program in Narrative Medicine at Columbia University, about the integration of medical humanities into traditional clinical practice.

Host: Bill Rutenberg, MD Guest: Peter Bach, MD As former senior advisor to administration centers of Medicare and Medicaid Services for Cancer initiatives, our guest Dr. Peter Bach talks with host Bill Rutenberg about lessons learned while working on behalf of Medicare and Medicaid. Some highlights of this interview include discussion about physicians' use of evidence-based medicine, coverage under evidence clause, pay for performance, no-bid contracts, DRG and more. Join us for a great discussion.

Host: Bill Rutenberg, MD Guest: Peter Bach, MD We know that early detection of cancer can save lives. With this in mind, the focus turns to finding imaging mechanisms that will facilitate early detection. Does CT screening provide accurate information on lung cancer? Should high-risk patients undergo PET scans? Host Dr. Bill Rutenberg speaks with Dr. Peter Bach, of the Memorial Sloan Kettering Cancer Center in New York, about the perceived values of screening for lung cancer.

Host: Bill Rutenberg, MD Guest: Peter Bach, MD Dr. Peter Bach, from the Memorial Sloan Kettering Cancer Center, talks with host Dr. Bill Rutenberg about racial disparities in medicine and treatment today. What are the reasons for this disparity, and how can we work to eliminate the difference? Join us to learn more.

Host: Bill Rutenberg, MD Guest: Peter Bach, MD What is keeping our society from moving forward in our ability to cure disease? How can what is learned in the lab be brought to the frontlines more quickly and efficiently? How can individual medical institutions work together to make a more profound difference in our healthcare system? Our Guest Dr. Peter Bach talks with host, Dr. Bill Rutenberg about the questions above in addition to his recent WSJ commentary entitled Why We'll Never Cure Cancer.

Host: Mark Nolan Hill, MD Guest: William Burke, MD Scientists at many institutions are researching to find neuroprotective agents for ALS. While today's guests research focuses on other neurological diseases, he recently wrote a commentary to a published neurology article about ALS research suggesting that the properties of a drug, Taxol should also be considered in animal models researching ALS. In this segment, Dr. Mark Nolan Hill talks with Dr. William Burke about ALS and why Taxol may be a worthwhile drug to examine in animal models as a neuoroprotective agent for ALS.

Host: Mark Nolan Hill, MD Guest: William Burke, MD In this discussion, Dr. Hill learns from Dr. William Burke about the latest research trying to link the dopamine theory to the alpha synuclean theory to better explain why Parkinson's Disease occurs. In this segment they also discuss current symptomatic treatment for Parkinson's Disease and the properties that would make up a more curative neuroprotective treatment.